BioNTech Has €16.8 Billion and Is Cutting 1,860 Jobs. That’s Not Distress. That’s a Pivot.

BioNTech is tearing down the manufacturing empire it built during the pandemic.

The German biotech announced Tuesday that it will exit operations at four manufacturing sites — Idar-Oberstein and Marburg in Germany, a facility in Singapore, and a plant it inherited from CureVac in Tübingen — eliminating up to 1,860 positions as it pivots hard toward oncology. The closures will be complete by the end of 2027, with Singapore concluding by Q1 2027. BioNTech is exploring divestment options for each site, including partial or total sales.

The cuts are real and they are fast. BioNTech CFO Ramón Zapata told analysts on the Q1 earnings call that consolidation efforts are focused on sites where capacity will become idle or underused within 24 months. That is not a gradual wind-down — that is a deliberate dismantling of excess pandemic infrastructure, done on a specific timeline tied to collapsing COVID-19 vaccine demand.

The numbers tell the story of why. Q1 2026 revenues fell to €118.1 million, down from €182.8 million in the same quarter last year, driven entirely by lower COVID-19 vaccine sales. BioNTech reaffirmed its full-year forecast of €2.0 to €2.3 billion in revenues — down from €2.9 billion in 2025 — and expects further declines in both the U.S. and European markets this year. Pfizer will fully take over production of the Comirnaty COVID-19 vaccine from the end of this year, cutting BioNTech out of manufacturing entirely.

The company simultaneously announced a $1 billion share repurchase program, a move that signals management's view that the stock is undervalued given the cash position of €16.8 billion — even as it cuts 1,860 jobs.

The manufacturing footprint being exited is remarkable in its scale. The Marburg facility alone houses eight production suites capable of producing up to 3 billion mRNA vaccine doses annually, making it one of the largest sites of its kind in the world. The Idar-Oberstein site predates BioNTech's founding — it was established in 1997 and became a wholly owned BioNTech subsidiary in 2009, employing roughly 500 people manufacturing cell therapy products and clinical bulk mRNA. The Singapore plant was added in 2022 when BioNTech acquired it from Novartis, envisioning it would produce hundreds of millions of mRNA doses per year. The Tübingen site came via the €1.25 billion acquisition of CureVac completed last year.

Together these sites represent a capital-intensive infrastructure built for a pandemic that is now effectively over as a commercial opportunity.

The €500 million in annual savings BioNTech expects to realize by 2029 — relative to its 2025 cost base and CureVac's 2026 budget — will not flow to the bottom line as pure profit. The company acknowledged it does not yet know what it will cost to outsource manufacturing to CDMOs, transfer production to remaining sites, or exit the facilities. Those exit costs will be recorded as incurred.

The pivot to oncology is where BioNTech is asking investors to look past the contraction. Its leading programs include pumitamig, a PD-L1xVEGF-A bispecific being developed with Bristol-Myers Squibb, which has five pivotal trials initiated so far in 2026 across first-line triple-negative breast cancer, MSS-CRC, gastric cancer, and two NSCLC studies. Also in the pipeline: gotistobart (anti-CTLA-4), BNT323 (HER2-directed ADC), and mRNA cancer immunotherapies. BioNTech reaffirmed its goal of becoming a multi-product oncology company by 2030.

This is a different company than the one that arrived during the pandemic. BioNTech during COVID was effectively a one-product mRNA vaccine maker with a manufacturing partner in Pfizer. Today its pipeline spans bispecifics, ADCs, and multiple mRNA cancer programs — and its pipeline ambitions require different manufacturing expertise than making hundreds of millions of identical vaccine doses.

The timing of these cuts coincides with a leadership transition that adds another layer of uncertainty. Co-founders Ugur Sahin and Özlem Türeci plan to exit their roles as CEO and CMO respectively by the end of 2026 to launch a new company focused on next-generation mRNA technologies. BioNTech has begun searching for successors. The new venture, which the founders will lead, will compete for talent and intellectual property with the company they are leaving behind.

For the 1,860 workers at sites being closed, the human calculus is straightforward. For BioNTech, the question is whether a leaner, more focused oncology company can deliver on a 2030 vision while absorbing the costs of a pandemic-era unwind — all during a leadership transition.

The manufacturing sites are for sale. The timeline is tight. The founders are leaving. BioNTech is making its bet — and the clock on proving it works started this week.